Nurix Therapeutics Holds 2025 Annual Stockholders Meeting

An announcement from Nurix Therapeutics ( (NRIX) ) is now available.

On May 19, 2025, Nurix Therapeutics held its virtual 2025 Annual Meeting of Stockholders, where approximately 85.33% of the voting power was represented. Stockholders voted to elect three Class II directors, ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approve the compensation of named executive officers on a non-binding advisory basis.

The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.

Spark’s Take on NRIX Stock

According to Spark, TipRanks’ AI Analyst, NRIX is a Neutral.

Nurix Therapeutics is currently facing significant financial challenges, particularly in terms of profitability and cash flow sustainability. The stock’s technical indicators suggest ongoing downward pressure, and valuation metrics are unattractive due to negative earnings. Although a recent positive corporate development could aid future potential, it does not offset the immediate financial and operational concerns.

To see Spark’s full report on NRIX stock, click here.

More about Nurix Therapeutics

Nurix Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of therapies that modulate protein levels for the treatment of various diseases.

Average Trading Volume: 982,731

Technical Sentiment Signal: Sell

Current Market Cap: $728.8M

For an in-depth examination of NRIX stock, go to TipRanks’ Stock Analysis page.